# Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD

> **NCT01862926** · PHASE2,PHASE3 · COMPLETED · sponsor: **Royal Brompton & Harefield NHS Foundation Trust** · enrollment: 104 (actual)

## Conditions studied

- Interstitial Lung Disease
- Scleroderma
- Idiopathic Inflammatory Myositis
- Mixed Connective Tissue Disease

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01862926
- **Lead sponsor:** Royal Brompton & Harefield NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2021-01
- **Final completion:** 2021-01
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2021-10-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01862926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01862926, "Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01862926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*